Claims for Patent: 9,687,512

Summary for Patent: 9,687,512

Title:	Isolated cardiac stem cells and methods of their use
Abstract:	The present invention relates to isolated populations of cardiac stem cells. The invention provides methods for characterizing, isolating, and culturing cardiac stem cells from human tissue samples. The invention also provides compositions and methods useful for treating cardiac disease.
Inventor(s):	Gaballa; Mohamed A. (Peoria, AZ)
Assignee:	Banner Health (Phoenix, AZ)
Application Number:	14/645,420
Patent Claims:	1. A composition comprising: one or more isolated cardiac stem cells derived from non-embryonic tissue, wherein said cardiac stem cells express c-Kit, Nanog, Wt1 and Sox2 but not CD34 or CD45. 2. The composition of claim 1, wherein the tissue is human tissue. 3. The composition of claim 1, wherein the cardiac stem cells are human cardiac stem cells. 4. The composition of claim 1, wherein the cardiac stem cells further express one or more markers selected from the group consisting of Hey1, SMA, Vimentin, Cyclin D2, Snail, E-cadherin, Nkx2.5, GATA4, MHCa, TnT, KDR, CD105, CD90, CD29, and CD73. 5. The composition of claim 1, wherein the tissue is obtained from a subject having or suspected of having a cardiac disease. 6. A method for the isolation of cardiac stem cells, comprising the selective enrichment of cardiac stem cells which express c-Kit, Nanog, Wt1 and Sox2 but not CD34 or CD45. 7. The method of claim 6, further comprising dissociating a source of cardiac stem cells from a cardiac tissue sample; and identifying a cardiac stem cell expressing c-Kit, Nanog, Wt1 and Sox2. 8. The method of claim 6, further comprising centrifuging a suspension of cells from heart tissue of a subject on a density gradient; isolating a layer of cells comprising cardiac stem cells; culturing the isolated cells until a population of cardiac stem cells is detectable. 9. The method of claim 6, further comprising obtaining heart tissue from a subject; digesting the heart tissue with collagenase. 10. The method of claim 6, further comprising obtaining heart tissue from a subject having or suspected of having a cardiac disease. 11. The method of claim 6, wherein the cardiac stem cells further express one or more markers selected from the group consisting of Hey1, SMA, Vimentin, Cyclin D2, Snail, E-cadherin, Nkx2.5, GATA4, MHCa, TnT, KDR, CD105, CD90, CD29, and CD73. 12. A method of treating a subject suffering from heart disease, comprising administering to the subject an effective dose of cardiac stem cells, wherein the cardiac stem cells express c-Kit, Nanog, Wt1 and Sox2 but not CD34 or CD45. 13. The method of claim 12, whereby the cardiac stem cells proliferate and differentiate to produce cardiomyocytes. 14. The method of claim 12, wherein the subject has a heart disease selected from the group consisting of chronic heart failure, myocardial infarction, congestive heart failure, congenital heart disease, cardiomyopathy, pericarditis, angina, and coronary artery disease. 15. The method of claim 12, further comprising administering an agent to the subject. 16. The method of claim 15, wherein the agent is selected from the group consisting of an ACE inhibitor, an aldosterone inhibitor, an angiotensin II receptor blocker, a beta-blocker, a calcium channel blocker, a statin, digoxin, a diuretic, a vasodilator, and an anticoagulant. 17. The method of claim 12, further comprising administering an agent to the cardiac stem cells prior to administering the cardiac stem cells to the subject. 18. The method of claim 17, wherein the agent is selected from the group consisting of PDGF, EGF, FGF, NGF, EPO, IGF-1, IGF-2, G-CSF, IL-6 INF, Stem Cell Factor, and TNF-.alpha.. 19. The method of claim 12, wherein the cardiac stem cells further express one or more markers selected from the group consisting of Hey1, SMA, Vimentin, Cyclin D2, Snail, E-cadherin, Nkx2.5, GATA4, MHCa, TnT, KDR, CD105, CD90, CD29, and CD73.

Details for Patent 9,687,512

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2034-03-12